AllianceBernstein’s Relmada Therapeutics RLMD Stock Holding History

AllianceBernstein’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-30,400	Closed	-$68.7K	–	3233
2023 Q1	$68.7K	Hold	30,400	–	–	﹤0.01%	3061
2022 Q4	$106K	Buy	30,400 +12,500	+70%	+$110K	﹤0.01%	3110
2022 Q3	$663K	Sell	17,900 -59,132	-77%	-$1.64M	﹤0.01%	2508
2022 Q2	$1.46M	Buy	77,032 +59,132	+330%	+$1.29M	﹤0.01%	2145
2022 Q1	$483K	Hold	17,900	–	–	﹤0.01%	2699
2021 Q4	$403K	Hold	17,900	–	–	﹤0.01%	2825
2021 Q3	$469K	Hold	17,900	–	–	﹤0.01%	2777
2021 Q2	$573K	Buy	17,900 +2,200	+14%	+$76.4K	﹤0.01%	2758
2021 Q1	$553K	Hold	15,700	–	–	﹤0.01%	2626
2020 Q4	$503K	Sell	15,700 -1,700	-10%	-$58.4K	﹤0.01%	2590
2020 Q3	$655K	Sell	17,400 -600	-3%	-$23.2K	﹤0.01%	2394
2020 Q2	$806K	Buy	+18,000	New	+$761K	﹤0.01%	2309

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

AllianceBernstein's RLMD Position: Q2 2023 in Review

AllianceBernstein sold out of Relmada Therapeutics (RLMD) in Q2 2023, closing a stake of 30,400 shares — an estimated $68.7K sold.

AllianceBernstein first reported a position in RLMD in Q2 2020 and held it in 12 quarters. The position peaked at $1.46M in Q2 2022. 95 funds tracked by Wall St. Rank hold RLMD as of Q2 2023.

AllianceBernstein reported no remaining Relmada Therapeutics position as of Q2 2023 after selling out during the quarter.
AllianceBernstein sold 30,400 Relmada Therapeutics shares in Q2 2023, an estimated $68.7K.
AllianceBernstein first reported a position in Relmada Therapeutics in Q2 2020 and held it in 12 quarters.
AllianceBernstein's Relmada Therapeutics position peaked at $1.46M in Q2 2022.
95 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2023.

Based on AllianceBernstein's 13F filing for Q2 2023, filed 15 Aug 2023.